| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Veterans | 20 | 2026 | 1753 | 3.900 |
Why?
|
| Brain Injuries, Traumatic | 9 | 2024 | 323 | 3.110 |
Why?
|
| Brain Injuries | 21 | 2019 | 702 | 2.900 |
Why?
|
| Stroke | 25 | 2025 | 1060 | 2.610 |
Why?
|
| Stress Disorders, Post-Traumatic | 11 | 2025 | 640 | 2.410 |
Why?
|
| Depressive Disorder | 23 | 2018 | 460 | 2.340 |
Why?
|
| REM Sleep Behavior Disorder | 5 | 2025 | 19 | 2.300 |
Why?
|
| Brain Concussion | 5 | 2026 | 248 | 1.950 |
Why?
|
| Mood Disorders | 13 | 2015 | 128 | 1.920 |
Why?
|
| Depression | 21 | 2023 | 1310 | 1.660 |
Why?
|
| Transcranial Magnetic Stimulation | 6 | 2017 | 79 | 1.460 |
Why?
|
| Antidepressive Agents | 11 | 2023 | 318 | 1.440 |
Why?
|
| Parkinson Disease | 9 | 2025 | 722 | 1.350 |
Why?
|
| Citalopram | 8 | 2016 | 28 | 1.190 |
Why?
|
| Cerebrovascular Disorders | 3 | 2019 | 112 | 1.090 |
Why?
|
| Brain | 15 | 2022 | 3170 | 0.920 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2026 | 251 | 0.910 |
Why?
|
| Impulsive Behavior | 2 | 2025 | 161 | 0.900 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2025 | 5 | 0.890 |
Why?
|
| Prodromal Symptoms | 1 | 2025 | 10 | 0.880 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2025 | 33 | 0.880 |
Why?
|
| Cognition Disorders | 13 | 2014 | 552 | 0.870 |
Why?
|
| Dreams | 2 | 2025 | 23 | 0.830 |
Why?
|
| Vagus Nerve Stimulation | 2 | 2022 | 67 | 0.790 |
Why?
|
| Persian Gulf Syndrome | 1 | 2023 | 16 | 0.780 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2022 | 3752 | 0.730 |
Why?
|
| Cerebral Cortex | 7 | 2017 | 448 | 0.720 |
Why?
|
| Humans | 111 | 2026 | 130555 | 0.710 |
Why?
|
| Middle Aged | 51 | 2026 | 28415 | 0.710 |
Why?
|
| Male | 78 | 2026 | 64534 | 0.690 |
Why?
|
| Aged | 52 | 2025 | 20899 | 0.680 |
Why?
|
| Mental Disorders | 6 | 2018 | 902 | 0.660 |
Why?
|
| Blast Injuries | 2 | 2018 | 60 | 0.640 |
Why?
|
| Psychiatric Status Rating Scales | 23 | 2020 | 831 | 0.640 |
Why?
|
| Armed Conflicts | 1 | 2020 | 7 | 0.630 |
Why?
|
| Adult | 37 | 2026 | 31157 | 0.620 |
Why?
|
| Neuropsychological Tests | 21 | 2022 | 953 | 0.620 |
Why?
|
| Parasomnias | 1 | 2019 | 4 | 0.610 |
Why?
|
| Sertraline | 2 | 2017 | 45 | 0.610 |
Why?
|
| Unconsciousness | 1 | 2019 | 28 | 0.610 |
Why?
|
| Combat Disorders | 1 | 2019 | 21 | 0.610 |
Why?
|
| GABA Agents | 1 | 2019 | 20 | 0.600 |
Why?
|
| Head Injuries, Closed | 6 | 2006 | 46 | 0.590 |
Why?
|
| Acceptance and Commitment Therapy | 1 | 2020 | 45 | 0.580 |
Why?
|
| War-Related Injuries | 1 | 2018 | 3 | 0.570 |
Why?
|
| Valproic Acid | 1 | 2019 | 140 | 0.560 |
Why?
|
| Amygdala | 2 | 2017 | 74 | 0.560 |
Why?
|
| Psychotherapy | 5 | 2016 | 249 | 0.560 |
Why?
|
| Female | 70 | 2026 | 70425 | 0.550 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 99 | 0.540 |
Why?
|
| Alcoholism | 2 | 2019 | 244 | 0.540 |
Why?
|
| Cross-Sectional Studies | 10 | 2024 | 3797 | 0.540 |
Why?
|
| Chronic Pain | 1 | 2020 | 163 | 0.520 |
Why?
|
| Military Personnel | 2 | 2017 | 209 | 0.520 |
Why?
|
| Stress, Psychological | 2 | 2020 | 538 | 0.520 |
Why?
|
| Iraq War, 2003-2011 | 5 | 2025 | 128 | 0.480 |
Why?
|
| Double-Blind Method | 15 | 2021 | 1621 | 0.460 |
Why?
|
| Polysomnography | 3 | 2025 | 155 | 0.450 |
Why?
|
| Dementia | 4 | 2011 | 433 | 0.450 |
Why?
|
| Amyloid | 1 | 2015 | 74 | 0.450 |
Why?
|
| Psychotropic Drugs | 2 | 2014 | 119 | 0.440 |
Why?
|
| Models, Theoretical | 1 | 2017 | 360 | 0.440 |
Why?
|
| Comorbidity | 8 | 2020 | 1583 | 0.440 |
Why?
|
| Cerebrovascular Circulation | 3 | 2015 | 481 | 0.430 |
Why?
|
| Social Adjustment | 6 | 2010 | 77 | 0.430 |
Why?
|
| Afghan Campaign 2001- | 4 | 2025 | 120 | 0.430 |
Why?
|
| Anxiety Disorders | 10 | 2018 | 726 | 0.420 |
Why?
|
| Epilepsy | 1 | 2022 | 864 | 0.420 |
Why?
|
| Cognition | 6 | 2022 | 817 | 0.410 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2024 | 1272 | 0.410 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2014 | 1444 | 0.390 |
Why?
|
| Apathy | 3 | 2022 | 12 | 0.380 |
Why?
|
| Problem Solving | 4 | 2016 | 61 | 0.370 |
Why?
|
| Skin | 1 | 2015 | 539 | 0.360 |
Why?
|
| Case-Control Studies | 9 | 2020 | 3355 | 0.360 |
Why?
|
| Oxygen | 1 | 2015 | 550 | 0.350 |
Why?
|
| Aggression | 4 | 2024 | 218 | 0.350 |
Why?
|
| Alzheimer Disease | 8 | 2011 | 878 | 0.350 |
Why?
|
| Mental Competency | 1 | 2011 | 55 | 0.340 |
Why?
|
| Huntington Disease | 5 | 2014 | 124 | 0.340 |
Why?
|
| Treatment Outcome | 17 | 2025 | 12865 | 0.330 |
Why?
|
| Pilot Projects | 3 | 2025 | 1447 | 0.330 |
Why?
|
| Diagnosis, Differential | 9 | 2019 | 1877 | 0.330 |
Why?
|
| Limbic System | 1 | 2010 | 23 | 0.310 |
Why?
|
| Brain Diseases, Metabolic | 1 | 2010 | 19 | 0.310 |
Why?
|
| Affective Symptoms | 1 | 2010 | 62 | 0.310 |
Why?
|
| Transcranial Direct Current Stimulation | 2 | 2020 | 21 | 0.310 |
Why?
|
| Emotions | 4 | 2018 | 350 | 0.300 |
Why?
|
| Statistics as Topic | 1 | 2010 | 242 | 0.290 |
Why?
|
| Follow-Up Studies | 13 | 2016 | 5164 | 0.290 |
Why?
|
| Anger | 2 | 2025 | 31 | 0.280 |
Why?
|
| Brain Mapping | 5 | 2015 | 381 | 0.280 |
Why?
|
| Severity of Illness Index | 15 | 2020 | 3031 | 0.280 |
Why?
|
| Antidepressive Agents, Second-Generation | 4 | 2016 | 31 | 0.280 |
Why?
|
| Family Health | 1 | 2009 | 241 | 0.280 |
Why?
|
| Stroke Rehabilitation | 4 | 2013 | 65 | 0.270 |
Why?
|
| Motivation | 1 | 2010 | 327 | 0.270 |
Why?
|
| International Classification of Diseases | 2 | 2024 | 92 | 0.260 |
Why?
|
| Bipolar Disorder | 4 | 2017 | 345 | 0.250 |
Why?
|
| Activities of Daily Living | 9 | 2013 | 388 | 0.250 |
Why?
|
| Memory Disorders | 2 | 2017 | 201 | 0.250 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 9 | 2011 | 225 | 0.240 |
Why?
|
| Electric Stimulation Therapy | 2 | 2004 | 88 | 0.230 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2021 | 87 | 0.230 |
Why?
|
| Psychotherapy, Group | 1 | 2025 | 58 | 0.230 |
Why?
|
| Alcohol-Related Disorders | 1 | 2005 | 35 | 0.220 |
Why?
|
| Pyrrolidinones | 3 | 2010 | 22 | 0.220 |
Why?
|
| Multiple Trauma | 2 | 2021 | 62 | 0.220 |
Why?
|
| Behavior, Animal | 2 | 2018 | 490 | 0.220 |
Why?
|
| Statistics, Nonparametric | 5 | 2012 | 424 | 0.210 |
Why?
|
| Agnosia | 3 | 2010 | 6 | 0.210 |
Why?
|
| Cognitive Dysfunction | 2 | 2021 | 337 | 0.200 |
Why?
|
| Prospective Studies | 8 | 2024 | 6438 | 0.200 |
Why?
|
| Gulf War | 1 | 2023 | 9 | 0.200 |
Why?
|
| Young Adult | 7 | 2020 | 10015 | 0.200 |
Why?
|
| United States | 6 | 2025 | 11883 | 0.190 |
Why?
|
| Aspartic Acid | 3 | 2014 | 72 | 0.190 |
Why?
|
| Positron-Emission Tomography | 3 | 2014 | 290 | 0.190 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2014 | 125 | 0.190 |
Why?
|
| Aphasia | 1 | 2022 | 14 | 0.190 |
Why?
|
| Neurocognitive Disorders | 2 | 1993 | 74 | 0.190 |
Why?
|
| Hippocampus | 2 | 2007 | 797 | 0.180 |
Why?
|
| Surveys and Questionnaires | 5 | 2024 | 4034 | 0.180 |
Why?
|
| Neurologic Examination | 8 | 2014 | 187 | 0.180 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2014 | 591 | 0.180 |
Why?
|
| Reading | 2 | 2014 | 75 | 0.180 |
Why?
|
| Vagus Nerve | 1 | 2022 | 50 | 0.180 |
Why?
|
| Attention | 2 | 2022 | 191 | 0.180 |
Why?
|
| Factor Analysis, Statistical | 2 | 2018 | 236 | 0.170 |
Why?
|
| Geriatric Assessment | 3 | 2011 | 183 | 0.170 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2023 | 321 | 0.170 |
Why?
|
| Temporal Lobe | 2 | 2000 | 110 | 0.170 |
Why?
|
| Rivastigmine | 1 | 2021 | 15 | 0.170 |
Why?
|
| Regression Analysis | 4 | 2017 | 760 | 0.170 |
Why?
|
| Phonetics | 1 | 2000 | 24 | 0.160 |
Why?
|
| Prevalence | 5 | 2020 | 2688 | 0.160 |
Why?
|
| Memory, Short-Term | 1 | 2022 | 139 | 0.160 |
Why?
|
| Disability Evaluation | 2 | 2011 | 190 | 0.160 |
Why?
|
| Language Tests | 1 | 2000 | 23 | 0.160 |
Why?
|
| Sleep Wake Disorders | 2 | 2021 | 202 | 0.160 |
Why?
|
| Recovery of Function | 3 | 2013 | 449 | 0.160 |
Why?
|
| Longitudinal Studies | 4 | 2018 | 1486 | 0.160 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 6800 | 0.160 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2014 | 255 | 0.160 |
Why?
|
| Intelligence | 1 | 2000 | 101 | 0.160 |
Why?
|
| Cluster Headache | 1 | 1999 | 2 | 0.150 |
Why?
|
| Age of Onset | 3 | 2011 | 597 | 0.150 |
Why?
|
| Alcohol Deterrents | 1 | 2019 | 12 | 0.150 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 903 | 0.150 |
Why?
|
| Self Administration | 1 | 2019 | 49 | 0.150 |
Why?
|
| Personality Inventory | 4 | 2009 | 178 | 0.150 |
Why?
|
| Psychopharmacology | 1 | 2019 | 14 | 0.150 |
Why?
|
| Naltrexone | 1 | 2019 | 70 | 0.150 |
Why?
|
| Injury Severity Score | 2 | 2012 | 233 | 0.140 |
Why?
|
| Substance-Related Disorders | 2 | 2014 | 489 | 0.140 |
Why?
|
| Electroconvulsive Therapy | 2 | 2014 | 81 | 0.140 |
Why?
|
| Point Mutation | 1 | 2000 | 332 | 0.140 |
Why?
|
| Anxiety | 2 | 2017 | 1007 | 0.140 |
Why?
|
| Age Factors | 3 | 2017 | 2830 | 0.140 |
Why?
|
| Glasgow Coma Scale | 5 | 2005 | 203 | 0.140 |
Why?
|
| Nortriptyline | 3 | 2011 | 5 | 0.140 |
Why?
|
| Risk | 1 | 2020 | 724 | 0.140 |
Why?
|
| Recurrence | 2 | 2019 | 1478 | 0.140 |
Why?
|
| Fluoxetine | 3 | 2011 | 45 | 0.130 |
Why?
|
| Neurofeedback | 1 | 2017 | 5 | 0.130 |
Why?
|
| Motor Skills | 1 | 2018 | 74 | 0.130 |
Why?
|
| Membrane Glycoproteins | 1 | 2020 | 408 | 0.130 |
Why?
|
| Spatial Memory | 1 | 2017 | 29 | 0.130 |
Why?
|
| Prefrontal Cortex | 2 | 2014 | 209 | 0.130 |
Why?
|
| Denmark | 1 | 2016 | 28 | 0.120 |
Why?
|
| Pain Management | 1 | 2019 | 205 | 0.120 |
Why?
|
| Executive Function | 3 | 2013 | 122 | 0.120 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 58 | 0.120 |
Why?
|
| Cerebral Hemorrhage | 1 | 2018 | 156 | 0.120 |
Why?
|
| Models, Statistical | 3 | 2011 | 484 | 0.120 |
Why?
|
| Risk Factors | 5 | 2015 | 10967 | 0.120 |
Why?
|
| Hospitals, University | 1 | 2016 | 103 | 0.120 |
Why?
|
| Encephalitis | 1 | 2017 | 123 | 0.120 |
Why?
|
| Atrophy | 3 | 2006 | 248 | 0.120 |
Why?
|
| Time Perception | 1 | 2015 | 9 | 0.120 |
Why?
|
| Connectome | 1 | 2017 | 111 | 0.110 |
Why?
|
| Osteoarthritis, Knee | 1 | 2019 | 282 | 0.110 |
Why?
|
| Arousal | 1 | 2015 | 75 | 0.110 |
Why?
|
| Mutation, Missense | 1 | 2000 | 924 | 0.110 |
Why?
|
| Interpersonal Relations | 2 | 2013 | 221 | 0.110 |
Why?
|
| Prognosis | 5 | 2015 | 4867 | 0.110 |
Why?
|
| Language | 3 | 2022 | 215 | 0.110 |
Why?
|
| Motor Activity | 2 | 2017 | 490 | 0.110 |
Why?
|
| Psychometrics | 5 | 2009 | 675 | 0.110 |
Why?
|
| Linear Models | 2 | 2013 | 686 | 0.100 |
Why?
|
| Neuropsychiatry | 1 | 2014 | 12 | 0.100 |
Why?
|
| Gyrus Cinguli | 1 | 2015 | 131 | 0.100 |
Why?
|
| Semantics | 1 | 2014 | 47 | 0.100 |
Why?
|
| Dominance, Cerebral | 2 | 2010 | 49 | 0.100 |
Why?
|
| Social Perception | 1 | 2014 | 52 | 0.100 |
Why?
|
| Comprehension | 1 | 2014 | 80 | 0.100 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2014 | 83 | 0.100 |
Why?
|
| Nootropic Agents | 2 | 2010 | 27 | 0.100 |
Why?
|
| Hospitals, Veterans | 1 | 2015 | 337 | 0.100 |
Why?
|
| Quality of Life | 1 | 2023 | 2074 | 0.100 |
Why?
|
| Apolipoproteins E | 1 | 2014 | 187 | 0.100 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 160 | 0.100 |
Why?
|
| Brain Injury, Chronic | 2 | 2004 | 17 | 0.100 |
Why?
|
| Time Factors | 6 | 2018 | 6215 | 0.090 |
Why?
|
| Schizophrenia | 1 | 2015 | 323 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2000 | 1590 | 0.090 |
Why?
|
| Psychomotor Performance | 2 | 2004 | 173 | 0.090 |
Why?
|
| Electromagnetic Fields | 2 | 2002 | 24 | 0.090 |
Why?
|
| Aging | 1 | 1999 | 1244 | 0.080 |
Why?
|
| Heart Rate | 2 | 2017 | 574 | 0.080 |
Why?
|
| Brain Ischemia | 2 | 2013 | 268 | 0.080 |
Why?
|
| Movement Disorders | 1 | 2013 | 220 | 0.080 |
Why?
|
| Nerve Net | 2 | 2010 | 259 | 0.080 |
Why?
|
| Perceptual Disorders | 1 | 2010 | 4 | 0.080 |
Why?
|
| Frontal Lobe | 3 | 2007 | 110 | 0.080 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 338 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 461 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 1375 | 0.080 |
Why?
|
| Argentina | 3 | 2011 | 54 | 0.080 |
Why?
|
| Choline | 1 | 2010 | 48 | 0.080 |
Why?
|
| Iowa | 2 | 2013 | 13 | 0.080 |
Why?
|
| Family | 1 | 2013 | 586 | 0.080 |
Why?
|
| Registries | 1 | 2016 | 1614 | 0.070 |
Why?
|
| Glucose | 1 | 2014 | 851 | 0.070 |
Why?
|
| Neuroimaging | 1 | 2012 | 382 | 0.070 |
Why?
|
| Expressed Emotion | 1 | 2009 | 8 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2024 | 298 | 0.070 |
Why?
|
| Thalamus | 2 | 2010 | 91 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2009 | 243 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2017 | 17557 | 0.070 |
Why?
|
| Autonomic Nervous System | 1 | 2008 | 48 | 0.070 |
Why?
|
| Dysthymic Disorder | 1 | 2008 | 7 | 0.070 |
Why?
|
| Secondary Prevention | 1 | 2009 | 216 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2014 | 1342 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1216 | 0.070 |
Why?
|
| Acute Disease | 3 | 2018 | 1154 | 0.070 |
Why?
|
| Brain Chemistry | 1 | 2007 | 111 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2009 | 150 | 0.060 |
Why?
|
| Dangerous Behavior | 1 | 2007 | 11 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2024 | 2901 | 0.060 |
Why?
|
| Adolescent | 6 | 2020 | 20774 | 0.060 |
Why?
|
| Delusions | 1 | 2006 | 17 | 0.060 |
Why?
|
| Organ Size | 1 | 2006 | 410 | 0.060 |
Why?
|
| Intelligence Tests | 2 | 2004 | 61 | 0.060 |
Why?
|
| Putamen | 1 | 2005 | 25 | 0.060 |
Why?
|
| Employment | 1 | 2005 | 71 | 0.050 |
Why?
|
| Affect | 3 | 2009 | 161 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2005 | 3678 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2005 | 169 | 0.050 |
Why?
|
| Laughter | 1 | 2004 | 9 | 0.050 |
Why?
|
| Crying | 1 | 2004 | 12 | 0.050 |
Why?
|
| Brain Infarction | 1 | 2004 | 28 | 0.050 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2004 | 43 | 0.050 |
Why?
|
| Verbal Learning | 1 | 2004 | 67 | 0.050 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2003 | 28 | 0.050 |
Why?
|
| Causality | 1 | 2004 | 90 | 0.050 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2003 | 30 | 0.050 |
Why?
|
| Brain Damage, Chronic | 2 | 2013 | 27 | 0.050 |
Why?
|
| Basal Ganglia | 3 | 2010 | 60 | 0.050 |
Why?
|
| Language Therapy | 1 | 2022 | 2 | 0.050 |
Why?
|
| Behavior Therapy | 1 | 2005 | 271 | 0.050 |
Why?
|
| Violence | 1 | 2024 | 128 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 5049 | 0.040 |
Why?
|
| Transdermal Patch | 1 | 2021 | 7 | 0.040 |
Why?
|
| Epidemiologic Measurements | 1 | 2000 | 3 | 0.040 |
Why?
|
| Wechsler Scales | 1 | 2000 | 18 | 0.040 |
Why?
|
| Protons | 2 | 2014 | 94 | 0.040 |
Why?
|
| Mental Health | 1 | 2024 | 370 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2003 | 1484 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 347 | 0.040 |
Why?
|
| Presenilin-1 | 1 | 2000 | 52 | 0.040 |
Why?
|
| Research Design | 1 | 2024 | 712 | 0.040 |
Why?
|
| Brain Waves | 1 | 2020 | 42 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 815 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 1391 | 0.040 |
Why?
|
| Cerebral Infarction | 1 | 1999 | 47 | 0.040 |
Why?
|
| Tomography, Emission-Computed | 1 | 1999 | 35 | 0.040 |
Why?
|
| Sleep | 1 | 2021 | 371 | 0.030 |
Why?
|
| Brazil | 1 | 2018 | 116 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2000 | 778 | 0.030 |
Why?
|
| Disease Progression | 3 | 2013 | 2193 | 0.030 |
Why?
|
| Incidence | 1 | 2005 | 3320 | 0.030 |
Why?
|
| Gliosis | 1 | 2017 | 31 | 0.030 |
Why?
|
| Serotonin | 1 | 1999 | 205 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2018 | 101 | 0.030 |
Why?
|
| Maze Learning | 1 | 2017 | 98 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 1994 | 2063 | 0.030 |
Why?
|
| Morbidity | 1 | 2018 | 257 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 1207 | 0.030 |
Why?
|
| Memory | 1 | 1999 | 352 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 725 | 0.030 |
Why?
|
| Microglia | 1 | 2017 | 146 | 0.030 |
Why?
|
| Pedigree | 1 | 2000 | 1674 | 0.030 |
Why?
|
| Models, Animal | 1 | 2017 | 453 | 0.030 |
Why?
|
| Personality Assessment | 2 | 2009 | 112 | 0.030 |
Why?
|
| Patient Safety | 1 | 2020 | 445 | 0.030 |
Why?
|
| Astrocytes | 1 | 2017 | 268 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 1157 | 0.030 |
Why?
|
| Dermatan Sulfate | 1 | 2013 | 1 | 0.030 |
Why?
|
| Trinucleotide Repeats | 1 | 2014 | 83 | 0.030 |
Why?
|
| Chondroitin Sulfates | 1 | 2013 | 13 | 0.020 |
Why?
|
| Social Participation | 1 | 2013 | 12 | 0.020 |
Why?
|
| Glasgow Outcome Scale | 1 | 2013 | 49 | 0.020 |
Why?
|
| Social Environment | 1 | 2014 | 112 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 1993 | 87 | 0.020 |
Why?
|
| Forecasting | 1 | 1994 | 350 | 0.020 |
Why?
|
| Logistic Models | 2 | 2008 | 1793 | 0.020 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 1993 | 41 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2017 | 849 | 0.020 |
Why?
|
| Animals | 3 | 2018 | 33856 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 723 | 0.020 |
Why?
|
| Functional Laterality | 2 | 2008 | 176 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2011 | 58 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 934 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1993 | 224 | 0.020 |
Why?
|
| Australia | 1 | 2011 | 171 | 0.020 |
Why?
|
| Mice | 2 | 2018 | 18215 | 0.020 |
Why?
|
| Phenotype | 1 | 2000 | 4478 | 0.020 |
Why?
|
| Awareness | 1 | 2010 | 79 | 0.020 |
Why?
|
| Hospitalization | 1 | 2018 | 1939 | 0.020 |
Why?
|
| Italy | 1 | 2008 | 112 | 0.020 |
Why?
|
| Internal-External Control | 1 | 2009 | 73 | 0.020 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2008 | 62 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2013 | 602 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1127 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2008 | 43 | 0.020 |
Why?
|
| Facial Expression | 1 | 2008 | 22 | 0.020 |
Why?
|
| Creatine | 1 | 2007 | 36 | 0.020 |
Why?
|
| Glutamates | 1 | 2007 | 51 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1993 | 2085 | 0.020 |
Why?
|
| Demography | 1 | 2008 | 237 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 4672 | 0.020 |
Why?
|
| Self Concept | 1 | 2008 | 157 | 0.020 |
Why?
|
| Capgras Syndrome | 1 | 2006 | 3 | 0.020 |
Why?
|
| Parents | 1 | 2013 | 1118 | 0.010 |
Why?
|
| Caudate Nucleus | 1 | 2005 | 34 | 0.010 |
Why?
|
| Dementia, Vascular | 1 | 2005 | 14 | 0.010 |
Why?
|
| Models, Psychological | 1 | 2005 | 138 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 484 | 0.010 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2005 | 72 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1610 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 564 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2003 | 230 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2000 | 76 | 0.010 |
Why?
|
| Caregivers | 1 | 2006 | 577 | 0.010 |
Why?
|
| Child | 1 | 2013 | 26175 | 0.010 |
Why?
|